TNK2 (Ab-284) Antibody

What is the biological significance of TNK2 phosphorylation at Tyr284?

The Tyr284 residue of TNK2 is a critical phosphorylation site that regulates TNK2 activation. When phosphorylated at this position, TNK2 undergoes conformational changes that enable its kinase activity. The kinase SRC has been implicated as a possible mediator that phosphorylates TNK2 at Tyr284 . This phosphorylation event is integral to TNK2's ability to transduce extracellular signals to cytosolic and nuclear effectors, ultimately influencing cell spreading, migration, survival, growth, and proliferation .

Interestingly, the Tyr284-phosphorylated form of TNK2 demonstrates distinct subcellular localization compared to the non-phosphorylated form. According to cellular localization studies, the phospho-Tyr284 form is expressed both in the membrane and nucleus, and co-localizes with EGFR on endosomes .

What validation methods have been used for phospho-TNK2 (Tyr284) antibodies?

Multiple validation approaches have been employed to ensure antibody specificity:

• Immunoblotting validation: Phospho-TNK2 antibodies have been evaluated by Western blotting in cell lysates such as A431 cells, with detection at the expected molecular weight .

• Peptide competition assays: Validation through preblocking experiments where the target band detection in cell lysates is prevented by preincubation with the immunogen phosphopeptide, but not with the corresponding non-phosphopeptide .

• Dot blot analysis: Demonstrating that the antibody detects the phospho-TNK2 (Tyr284) peptide but not the unmodified TNK2 peptide .

• Negative control experiments: Omitting the primary antibody during incubation to confirm specificity of signal in immunohistochemistry applications .

How is TNK2 expression distributed in normal versus cancer tissues?

TNK2 expression shows significant upregulation in various cancer types, particularly in triple-negative breast cancer (TNBC). In a comprehensive study of TNBC samples:

• 6% of TNBC patients showed strong positive TNK2 expression

• 14% exhibited moderate positive expression

• 22% displayed weak positive expression

• 58% were negative for TNK2 expression

This distribution pattern suggests that approximately 42% of TNBC cases express TNK2 at detectable levels, with 20% showing moderate to strong expression .

What is the correlation between TNK2 expression and cancer cell aggressiveness?

Research has established a significant correlation between TNK2 expression levels and cancer cell aggressiveness markers:

• Studies examining 26 TNBC cell lines found that TNK2 expression levels were significantly correlated with anchorage-independent growth capabilities .

• Higher TNK2 expression positively correlated with increased cellular invasiveness in matrigel invasion assays .

• Knockdown of TNK2 in TNBC cell lines with high TNK2 expression (MDA-MB-435, HCC1806, HCC70, and HCC1143) resulted in decreased proliferation and invasion, while similar knockdown in low TNK2-expressing cell lines (BT549, HCC1937, and HCC1569) had minimal effect .

These findings strongly suggest that TNK2 plays a functional role in promoting the oncogenic properties of TNBC cells, particularly in the subset of tumors with higher expression levels .

What is the recommended protocol for immunohistochemistry with TNK2 (Ab-284) antibody?

Based on published protocols for TNK2 phospho-antibody immunohistochemistry:

• Sample preparation:

  • Cut 4μm sections from formalin-fixed paraffin-embedded tissues

  • Transfer to adhesive-coated slides

• Deparaffinization:

  • Heat slides at 55°C for 30 minutes

  • Wash three times with xylene, 5 minutes each

• Rehydration:

  • Serial washes (5 minutes each) in 100%, 95%, and 80% ethanol

  • Final wash in distilled water

• Antigen retrieval:

  • Heat samples at 95°C for 30 minutes in 10 mmol/L sodium citrate (pH 6.0)

• Blocking and antibody incubation:

  • Block with universal blocking serum for 30 minutes

  • Incubate with rabbit polyclonal pTyr284-TNK2 antibody (1:300 dilution)

  • Incubate with biotin-labeled secondary antibody and streptavidin-peroxidase for 30 minutes each

• Detection:

  • Develop with 3,3'-diaminobenzidine substrate

  • Counterstain with hematoxylin

  • Dehydrate and seal with coverslips

Always include negative controls by omitting the primary antibody during incubation .

How should phosphorylation-specific TNK2 antibodies be stored for optimal performance?

Most manufacturers recommend:

• Store antibody at -20°C or -80°C for long-term storage

• Aliquot the antibody to avoid repeated freeze-thaw cycles

• For phospho-specific antibodies, some formulations include 50% glycerol, 0.02% sodium azide in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4

• Working dilutions should be prepared fresh before use

How can TNK2 (Ab-284) antibody be used to investigate TNK2's role in signaling pathways?

TNK2 phosphorylation at Tyr284 can be studied in the context of multiple signaling pathways:

• RAS/MAPK pathway investigation:

  • Co-immunoprecipitation experiments with TNK2 and pathway components

  • Western blotting for downstream targets like phosphorylated p44/42 MAPK

  • Examine how TNK2 phosphorylation changes upon pathway stimulation or inhibition

• TNK2 and PTPN11 (SHP2) interactions:

  • Studies have demonstrated that TNK2 enhances signaling of mutant PTPN11 through the RAS/MAPK pathway

  • Co-expression of PTPN11 E76K with TNK2 resulted in significantly increased phosphorylated p44/42 MAPK compared to cells expressing either protein alone

  • Interestingly, phosphorylation of TNK2 at Tyr284 was reduced when co-expressed with PTPN11, especially with mutant PTPN11

• Interactome analysis:

  • BioID and BioSITe (biotinylation site identification technology) methods can be combined with TNK2 antibodies to identify protein interaction networks

  • These approaches allow for mapping of TNK2's dynamic interactome under different cellular conditions

What controls should be included when studying TNK2 phosphorylation in cancer models?

Comprehensive controls for phospho-TNK2 studies should include:

• Positive controls:

  • Cell lines known to express high levels of phospho-TNK2 (e.g., A431 cells, MDA-MB-435)

  • Cells treated with growth factors or phosphatase inhibitors to increase phosphorylation

• Negative controls:

  • TNK2 knockdown using validated siRNAs

  • Non-phosphorylatable TNK2 mutants (Y284F)

  • Phosphatase treatment of lysates

  • Omission of primary antibody in immunostaining

• Specificity controls:

  • Peptide competition assays using phosphorylated and non-phosphorylated peptides

  • Comparison with total TNK2 antibody staining to normalize phosphorylation levels

• Functional validation:

  • Correlation of phospho-TNK2 levels with downstream signaling activation

  • Comparison with functional assays (invasion, proliferation) in the same cell models

How do TNK2 phosphorylation patterns correlate with different breast cancer subtypes?

TNK2 phosphorylation appears to be particularly relevant in triple-negative breast cancer:

• Analysis of breast cancer tissue microarrays (TMAs) containing samples of normal breast tissue, atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), and lymph node macro metastasis (LNMM) showed differential patterns of TNK2 phosphorylation .

• The phosphorylation status of TNK2 at Tyr284 correlates with disease progression in some breast cancer subtypes, with phospho-TNK2 demonstrated across multiple stages of cancer development .

• In a panel of 26 TNBC cell lines, the phosphorylation of TNK2 at multiple sites (pY284, pY518, pY859, and pY860) was detected, with pY518 being hyperphosphorylated in a majority of aggressive cell lines .

These findings suggest that monitoring TNK2 phosphorylation status, particularly at Tyr284, may have prognostic value in breast cancer and could potentially serve as a biomarker for disease progression or treatment response.

What evidence supports TNK2 as a therapeutic target in cancer?

Several lines of evidence establish TNK2 as a promising therapeutic target:

• Expression correlation with cancer aggressiveness:

  • Significant correlation between TNK2 expression levels and anchorage-independent growth

  • Association with cellular invasiveness in TNBC cell lines

• Functional validation through knockdown studies:

  • siRNA knockdown of TNK2 in TNBC cell lines with high TNK2 expression (MDA-MB-435, HCC1806, HCC70, and HCC1143) significantly reduced proliferation and invasion

  • Similar knockdown in low TNK2-expressing lines had minimal effect, suggesting specificity of targeting highly expressing tumors

• Synthetic lethality context:

  • TNK2 inhibition has demonstrated synthetic lethality in PTPN11-mutant leukemia

  • The interaction between TNK2 and PTPN11 suggests potential therapeutic opportunities in cancers with specific genetic backgrounds

These findings collectively suggest that targeting TNK2 kinase activity, particularly in tumors with high expression or phosphorylation levels, represents a potential therapeutic strategy that warrants further investigation.